Biocryst Pharmaceuticals (BCRX) Other financing activities (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Other financing activities for 17 consecutive years, with $6.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities rose 81.32% year-over-year to $6.2 million; the trailing twelve-month figure through Jun 2026 stood at $29.0 million (up 296.53% YoY), and the FY2025 full-year result was $9.1 million, up 164.66% from the prior year.
• Other financing activities slipped to $6.2 million in Q2 2026 per BCRX's latest filing, from $19.5 million in the prior quarter.
• Across five years, Other financing activities topped out at $19.5 million in Q1 2026 and bottomed at -$586000.0 in Q4 2024.
• Historically, Other financing activities has averaged $3.4 million across 5 years, with a median of $2.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Other financing activities sank 1602.56% in 2024, then surged 1195.83% in 2025.
• Over 5 years, Other financing activities stood at $4.0 million in 2022, then tumbled by 99.03% to $39000.0 in 2023, then tumbled by 1602.56% to -$586000.0 in 2024, then soared by 212.12% to $657000.0 in 2025, then surged by 844.14% to $6.2 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $6.2 million, $19.5 million, and $657000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.